Maze Therapeutics director granted 18,000 stock options
Maze Therapeutics, Inc. director Daniel K. Spiegelman received a grant of stock options covering 18,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Maze Therapeutics, Inc. director Daniel K. Spiegelman received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. They vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, subject to his continued service.
Insider Trade Summary
Grant/Award: 18,000 shares
Grant/Award
1 txn
Insider
SPIEGELMAN DANIEL K
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 18,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 18,000 contracts (Direct)
Footnotes (1)
- F1. The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
Key Figures
Options granted: 18,000 options
Exercise price: $23.58 per share
Underlying shares: 18,000 shares
+2 more
5 metrics
Options granted
18,000 options
Stock Option (Right to Buy) grant to director
Exercise price
$23.58 per share
Stock option strike price for underlying common stock
Underlying shares
18,000 shares
Common stock underlying granted options
Total derivative holdings after grant
18,000 options
Total stock options held following this transaction
Option expiration
June 7, 2036
Expiration date of granted stock options
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, annual stockholders meeting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 23.5800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-07T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual stockholders meeting financial
"the issuer's 2027 annual stockholders meeting"
vest financial
"The option shall vest and be fully exercisable"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Maze Therapeutics (MAZE) director Daniel Spiegelman report on this Form 4?
Maze Therapeutics director Daniel K. Spiegelman reported receiving a grant of stock options for 18,000 shares of common stock. These options were awarded as compensation, not purchased in the open market, and reflect a new derivative position rather than a cash transaction.
How many Maze Therapeutics (MAZE) stock options were granted and at what price?
Daniel Spiegelman was granted stock options on 18,000 shares of Maze Therapeutics common stock. The options have an exercise price of $23.58 per share, meaning he can buy shares at that price once the options vest and become exercisable.
When do Daniel Spiegelman’s Maze Therapeutics (MAZE) options vest and become exercisable?
The granted options vest and become fully exercisable on the earlier of the issuer’s 2027 annual stockholders meeting or June 8, 2027. Vesting is contingent on Daniel Spiegelman’s continued service to Maze Therapeutics through that vesting date.
What is the expiration date of the Maze Therapeutics (MAZE) stock options granted to Daniel Spiegelman?
The stock options granted to Daniel Spiegelman expire on June 7, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase Maze Therapeutics common shares at the specified exercise price.
Is the Maze Therapeutics (MAZE) Form 4 transaction an open-market buy or a compensation grant?
The Form 4 shows a compensation-related grant, not an open‑market purchase. The transaction code is “A,” indicating a grant, award or other acquisition of derivative securities, specifically stock options, with no cash price paid at the time of grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
